journal article·2024-07Open access

Lipid Nanocarrier‐Based mRNA Therapy: Challenges and Promise for Clinical Transformation

Wenchao Li, Chen Wang, Yifei Zhang, Yuan Lu

Small· Volume 20· Issue 28

Abstract

Abstract Due to the outbreak of novel coronavirus pneumonia, messenger RNA (mRNA) technology has attracted heated attention. A specific, safe, and efficient mRNA delivery system is needed. Lipid nanocarriers have become attractive carriers for mRNA delivery due to their high delivery efficiency, few side effects, and easy modification to change their structures and functions. To achieve the desired biological effect, lipid nanocarriers must reach the designated location for effective drug delivery. Therefore, the effects of the composition of lipid nanocarriers on their key properties are briefly reviewed. In addition, the progress of smart drug delivery by changing the composition of lipid nanocarriers is summarized, and the importance of component design and structure is emphasized. Subsequently, this review summarizes the latest progress in lipid nanocarrier‐based mRNA technology and provides corresponding strategies for its current challenges, putting forward valuable information for the future design of lipid nanocarriers and mRNA.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Nanopore and Nanochannel Transport Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical Engineering Tsinghua University Beijing 100084 China

Key Laboratory of Industrial Biocatalysis Ministry of Education Tsinghua University Beijing 100084 China

State Key Laboratory of Chemical Resource Engineering Beijing University of Chemical Technology Beijing 100029 China

Beijing Advanced Innovation Center for Soft Matter Science and Engineering Beijing University of Chemical Technology Beijing 100029 China

Funding

National Natural Science Foundation of China · National Key Research and Development Program of China

References (100+)

Show source-provided references
1. 10.1146/annurev-bioeng-110220-03172210.1146/annurev-bioeng-110220-031722 ↗
2. 10.3390/pharmaceutics1504112710.3390/pharmaceutics15041127 ↗
3. 10.1002/adma.20230326110.1002/adma.202303261 ↗
4. 10.3390/pharmaceutics1412268210.3390/pharmaceutics14122682 ↗
5. 10.1038/s43586-022-00104-y10.1038/s43586-022-00104-y ↗
6. 10.1016/j.bioactmat.2022.11.01410.1016/j.bioactmat.2022.11.014 ↗
7. 10.2217/nnm-2022-002410.2217/nnm-2022-0024 ↗
8. 10.1016/S0022-2836(65)80093-610.1016/S0022-2836(65)80093-6 ↗
9. 10.1038/274923a010.1038/274923a0 ↗
10. 10.1126/science.743402510.1126/science.7434025 ↗
11. 10.1073/pnas.86.16.607710.1073/pnas.86.16.6077 ↗
12. 10.1016/0014-5793(90)81016-H10.1016/0014-5793(90)81016-H ↗
13. 10.1002/eji.183023074910.1002/eji.1830230749 ↗
14. 10.1021/acsnano.1c0499610.1021/acsnano.1c04996 ↗
15. 10.1038/s41578-021-00358-010.1038/s41578-021-00358-0 ↗
16. 10.1016/j.vaccine.2019.04.07410.1016/j.vaccine.2019.04.074 ↗
17. 10.1038/s41565-019-0591-y10.1038/s41565-019-0591-y ↗
18. 10.1016/j.apsb.2022.03.01110.1016/j.apsb.2022.03.011 ↗
19. 10.1016/j.addr.2022.11441610.1016/j.addr.2022.114416 ↗
20. 10.1016/j.addr.2020.06.00210.1016/j.addr.2020.06.002 ↗
21. 10.1016/j.omtm.2020.07.01510.1016/j.omtm.2020.07.015 ↗
22. 10.1038/s41467-021-27493-010.1038/s41467-021-27493-0 ↗
23. 10.1016/j.ymthe.2018.03.01010.1016/j.ymthe.2018.03.010 ↗
24. 10.1038/ncomms527710.1038/ncomms5277 ↗
25. 10.1002/smsc.20220007110.1002/smsc.202200071 ↗
26. 10.1016/j.jconrel.2022.11.03710.1016/j.jconrel.2022.11.037 ↗
27. 10.1038/s42003-021-02441-210.1038/s42003-021-02441-2 ↗
28. 10.1007/s40290-021-00417-510.1007/s40290-021-00417-5 ↗
29. 10.1016/j.jddst.2019.01.00410.1016/j.jddst.2019.01.004 ↗
30. 10.1016/j.jconrel.2012.11.01610.1016/j.jconrel.2012.11.016 ↗
31. 10.1021/acsnano.0c1006410.1021/acsnano.0c10064 ↗
32. 10.1007/s11095-022-03460-210.1007/s11095-022-03460-2 ↗
33. 10.1073/pnas.210925611810.1073/pnas.2109256118 ↗
34. 10.1038/s41571-023-00811-910.1038/s41571-023-00811-9 ↗
35. 10.1021/acs.accounts.1c0054410.1021/acs.accounts.1c00544 ↗
36. 10.1007/s12668-022-00941-x10.1007/s12668-022-00941-x ↗
37. 10.1080/1061186X.2018.152733710.1080/1061186X.2018.1527337 ↗
38. 10.1016/j.cis.2022.10275710.1016/j.cis.2022.102757 ↗
39. 10.1016/j.ultramic.2019.11284910.1016/j.ultramic.2019.112849 ↗
40. 10.1016/j.ymeth.2020.05.00110.1016/j.ymeth.2020.05.001 ↗
41. 10.1016/j.addr.2020.06.02210.1016/j.addr.2020.06.022 ↗
42. 10.3390/molecules2707220210.3390/molecules27072202 ↗
43. 10.1007/s00216-017-0527-z10.1007/s00216-017-0527-z ↗
44. 10.1016/j.colsurfa.2018.09.00610.1016/j.colsurfa.2018.09.006 ↗
45. 10.1016/j.talanta.2019.06.06210.1016/j.talanta.2019.06.062 ↗
46. 10.1016/j.partic.2010.01.00310.1016/j.partic.2010.01.003 ↗
47. 10.1002/elps.20120054910.1002/elps.201200549 ↗
48. Huang Y.‐X. · Acta Polym. Sin. · 2018 · 893
49. 10.2147/IJN.S33163910.2147/IJN.S331639 ↗
50. 10.3390/pharmaceutics1211109510.3390/pharmaceutics12111095 ↗
51. 10.1021/acsabm.1c0073210.1021/acsabm.1c00732 ↗
52. 10.1002/anie.20160845010.1002/anie.201608450 ↗
53. 10.1021/acsinfecdis.9b0008410.1021/acsinfecdis.9b00084 ↗
54. 10.1016/j.jconrel.2019.06.04210.1016/j.jconrel.2019.06.042 ↗
55. 10.1371/journal.pone.024100610.1371/journal.pone.0241006 ↗
56. 10.1126/sciadv.ade144410.1126/sciadv.ade1444 ↗
57. 10.1038/s41551-021-00786-x10.1038/s41551-021-00786-x ↗
58. 10.1038/s41587-023-01679-x10.1038/s41587-023-01679-x ↗
59. 10.1021/acsnano.2c0564710.1021/acsnano.2c05647 ↗
60. 10.1016/j.matt.2021.12.02210.1016/j.matt.2021.12.022 ↗
61. Vander Straeten A. · Nat. Biotechnol. · 2023
62. 10.1021/acs.molpharmaceut.2c0063510.1021/acs.molpharmaceut.2c00635 ↗
63. 10.1016/j.jconrel.2022.08.00110.1016/j.jconrel.2022.08.001 ↗
64. 10.3390/polym1206139710.3390/polym12061397 ↗
65. 10.1016/j.colsurfb.2016.07.06010.1016/j.colsurfb.2016.07.060 ↗
66. 10.3390/pharmaceutics1410219510.3390/pharmaceutics14102195 ↗
67. 10.1016/j.colsurfb.2022.11273710.1016/j.colsurfb.2022.112737 ↗
68. 10.3390/nano902019110.3390/nano9020191 ↗
69. 10.1016/j.lfs.2022.12113310.1016/j.lfs.2022.121133 ↗
70. 10.1039/C9TB02470K10.1039/C9TB02470K ↗
71. 10.1021/acsptsci.1c0006610.1021/acsptsci.1c00066 ↗
72. 10.1016/S0169-409X(01)00232-010.1016/S0169-409X(01)00232-0 ↗
73. 10.1016/j.msec.2020.11111610.1016/j.msec.2020.111116 ↗
74. 10.1016/j.colsurfa.2021.12677810.1016/j.colsurfa.2021.126778 ↗
75. 10.1016/j.jconrel.2018.10.01510.1016/j.jconrel.2018.10.015 ↗
76. 10.1021/acschembio.0c0000310.1021/acschembio.0c00003 ↗
77. 10.1038/s41565-020-0669-610.1038/s41565-020-0669-6 ↗
78. 10.1073/pnas.211627111910.1073/pnas.2116271119 ↗
79. 10.1016/j.bbagen.2012.03.01710.1016/j.bbagen.2012.03.017 ↗
80. 10.1186/s12967-022-03325-710.1186/s12967-022-03325-7 ↗
81. Tsai S. J. · BioRxiv · 2021
82. 10.1038/s41467-021-25839-210.1038/s41467-021-25839-2 ↗
83. 10.1002/adma.20210998410.1002/adma.202109984 ↗
84. 10.1186/s12951-021-00986-210.1186/s12951-021-00986-2 ↗
85. 10.1002/advs.20170061110.1002/advs.201700611 ↗
86. 10.1186/s12943-022-01509-910.1186/s12943-022-01509-9 ↗
87. 10.1002/adhm.20220303310.1002/adhm.202203033 ↗
88. 10.1016/S0140-6736(17)31665-310.1016/S0140-6736(17)31665-3 ↗
89. 10.1016/j.vaccine.2020.12.07010.1016/j.vaccine.2020.12.070 ↗
90. 10.1038/s41467-018-05482-010.1038/s41467-018-05482-0 ↗
91. 10.1016/j.ymthe.2020.04.01810.1016/j.ymthe.2020.04.018 ↗
92. 10.1038/s41541-021-00307-610.1038/s41541-021-00307-6 ↗
93. 10.1038/s41541-020-0163-z10.1038/s41541-020-0163-z ↗
94. 10.1021/acs.nanolett.6b0332910.1021/acs.nanolett.6b03329 ↗
95. 10.1021/acs.nanolett.1c0250310.1021/acs.nanolett.1c02503 ↗
96. 10.1021/acsbiomaterials.1c0153210.1021/acsbiomaterials.1c01532 ↗
97. 10.1126/sciadv.abj690110.1126/sciadv.abj6901 ↗
98. 10.1126/sciadv.abc945010.1126/sciadv.abc9450 ↗
99. 10.1038/s41565-022-01122-310.1038/s41565-022-01122-3 ↗
100. 10.1002/adma.20190257510.1002/adma.201902575 ↗